Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 225-533-8 | CAS number: 4904-61-4
Acute Toxicity: inhalation
Administrative data
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study
Data source
Referenceopen allclose all
- Reference Type:
- publication
- Title:
- Robust summary for 1,5,9-cyclododecatriene (revised).
- Author:
- DuPont Safety, Health & Environmental Excellence Center, Wilmington (Del., USA)
- Year:
- 2 003
- Bibliographic source:
- U.S. EPA, 46 pp
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 996
- Reference Type:
- publication
- Title:
- Initial submission: Letter from DuPont Chem to USEPA regarding an acute inhalation study in rats with 1,5,9-cyclododecatriene,
- Author:
- DuPont Chem.
- Year:
- 1 996
- Bibliographic source:
- dated 04/02/96. NTIS/OTS Microfiche 0558489, Doc 89-960000095.
Materials and methods
- Principles of method if other than guideline:
- Method: other: no data
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- Cyclododeca-1,5,9-triene
- EC Number:
- 225-533-8
- EC Name:
- Cyclododeca-1,5,9-triene
- Cas Number:
- 4904-61-4
- Molecular formula:
- C12H18
- IUPAC Name:
- cyclododeca-1,5,9-triene
- Reference substance name:
- 1,5,9-cyclododecatriene
- IUPAC Name:
- 1,5,9-cyclododecatriene
- Details on test material:
- 1,5,9-cyclododecatriene, purity 100 %
Constituent 1
Constituent 2
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ORGANISMS:
- Age: approximately 8 weeks
- Weight at study initiation: 242-291 g
Administration / exposure
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose only
- Vehicle:
- other: air
- Details on inhalation exposure:
- ADMINISTRATION:
- Type of exposure: nose only
- Concentrations: 6.1 mg/l; 8.1 mg/l
- Particle size: mass median aerodynamic diameters (MMAD) 2.8 - 2.9 um
- Type or preparation of particles: nebulizer
- Chamber temperature: 21-24°C
- Relaive humidity. 36.7-43.6 %
- Airflow: appr. 27 l/min - Analytical verification of test atmosphere concentrations:
- yes
- Remarks:
- vapor phase was measured by gaschromatography
- Duration of exposure:
- 4 h
- Concentrations:
- 6.1 mg/l; 8.1 mg/l
- No. of animals per sex per dose:
- 6
- Control animals:
- not specified
- Details on study design:
- EXAMINATIONS:
- Mortality and Clinical signs: During and immediately following exposure; 14 day observation period - Statistics:
- no data
Results and discussion
Effect levels
- Sex:
- male
- Dose descriptor:
- LC50
- Effect level:
- > 8.1 mg/L air
- Exp. duration:
- 4 h
- Mortality:
- Number of deaths at each dose: 1 during 8.1 mg/l exposure
- Clinical signs:
- other: During the exposures the rats exhibited diminished or no response to sound stimulus. Clinical signs noted in rats from both exposures included ocular and nasal discharges, irregular respiration, abnormal gait or mobility, and tremors. Additionally, th
- Body weight:
- slight to moderate weight losses day following exposure, began gaining weight subsequently and did not experience weight loss throughtout the
remainder of the recovery period - Gross pathology:
- no data
- Other findings:
- no other findings
Any other information on results incl. tables
no further remarks
Applicant's summary and conclusion
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: other: Regulation EC 1272/2008 (CLP)
- Conclusions:
- According to the results of the study it is concluded that the LC50 for male rats is greater than 8.1 mg/l air for the test item 1,5,9-cyclododecatriene under conditions of the study.
- Executive summary:
Two groups of 6 male rats each were exposed nose-only for a single, 4-hour periode to vapors of the test item 1,5,9 -Cyclododecatriene in air at chamber vapor concentrations of 6.1 or 8.1 mg/l. Mortality was 1/6 in the high dose group. Clinical signs noted in rats from both exposures included ocular and nasal discharges, irregular respiration, abnormal gait or mobility, and tremors. Additionally, the rats exposed to 8.1 mg/l exhibited aggressive behavior and vocalization. Tremors were observed only on test day 1 in both groups. Abnormal gait or mobility was observed only on test day 1 in rats exposed to 6.1 mg/l and up to 3 days following exposure in rats exposed to 8.1 mg/l. No clinical signs of toxicity were observed after day 4 following exposure.
Therefore it is concluded that the LC50 for male rats is greater than 8.1 mg/l air for the test item 1,5,9-cyclododecatriene under the conditions of the study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
